Navtemadlin (KRT-232) in combination with avelumab for patients with anti-PD-1/L1 treatment-naïve TP53WTMerkel cell carcinoma (MCC)

Autor: Wong, Michael K., Burgess, Melissa, Chandra, Sunandana, Schadendorf, Dirk, Silk, Ann, Olszanski, Anthony J., Grob, Jean-Jacques, Jang, Sekwon, Grewal, Jaspreet Singh, Lewis, Karl D., Fecher, Leslie, Rabinowits, Guilherme, Lebbe, Celeste, Martin-Liberal, Juan, Di Giacomo, Anna Maria, Friedlander, Philip, Brohl, Andrew S., Croft, Brandon, McGreivy, Jesse S., Rothbaum, Wayne P., Hanna, Glenn J., Kelly, Ciara M.
Zdroj: Journal of Investigative Dermatology; October 2022, Vol. 142 Issue: 10 p2841-2841, 1p
Databáze: Supplemental Index